Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.

PMID:29878848
Zhu J , He W , Ye M , Fu J , Chu YB , Zhao YY , Zhang YJ , Kuo D , Wu B
Future oncology (London, England)
To investigate the cost-effectiveness of afatinib and erlotinib as second-line therapy for advanced squamous cell carcinoma of the lung.


Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved